There are several targeted therapy options available for patients with hormone receptor-positive (HR+), metastatic breast cancer with germline mutations (BRCA 1 and 2, PALB2), such as CDK4/6 inhibitors (CDK4/6i) and poly (ADP-ribose) polymerase inhibitors (PARPi). However, further data is needed to better understand the optimal sequence of therapy.
A recent analysis, presented at ESMO 2024 in Barcelona by study author Gerneiva Parkinson, MD, MHS, in the Department of Medical Oncology at Stanford Medicine, sought to fill this knowledge gap (Abstract 342MO).
September 17, 2024
Read moreA new analysis suggests that olanzapine (5 mg for 6 days) coupled with 5-hydroxytryptamine type 3-receptor antagonist (5-HT3RA) and dexamethasone is an effective approach to reduce delayed and persistent nausea and vomiting among metastatic breast cancer patients treated with trastuzumab deruxtecan (T-DXd). These findings were recently presented during ESMO 2024 in Barcelona (Abstract 1816O) and simultaneously published in the Annals of Oncology (2024; doi:10.1016/j.annonc.2024.09.001).
September 18, 2024
Read moreAt the ESMO 2024 conference, new data from the largest prospective study to date on trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer (mBC) patients, including those with brain metastases, was presented, offering renewed hope for patients who have limited treatment options (Abstract LBA18).
September 17, 2024
Read moreFindings from the SUBITO trial, which explored intensified alkylating chemotherapy with autologous stem cell rescue (IACT) or conventional chemotherapy followed by olaparib (CCT-O) among Stage III, HER2-negative, homologous recombination-deficient breast cancer patients, were recently presented during ESMO 2024 in Barcelona (Abstract LBA14).
September 17, 2024
Read moreThe Phase II ICARUS-BREAST01 trial has shown promising efficacy and manageable safety for the novel therapy patritumab deruxtecan (HER3-DXd) in patients with advanced hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer. Presented at the ESMO Congress 2024 conference by Barbara Pistilli, MD, these findings provide a potential option for patients who have progressed after multiple lines of therapy.
September 18, 2024
Read moreThe CAPItello-290 Phase III trial, long-awaited by the oncology community, delivered mixed results for the combination of capivasertib and paclitaxel as a first-line treatment for metastatic triple-negative breast cancer (mTNBC). Although the trial did not achieve its primary endpoint of improving overall survival (OS) in both the general mTNBC population and those with specific tumor mutations, the combination treatment showed a notable progression-free survival (PFS) advantage. These findings offer important insights into the potential therapeutic role of capivasertib in managing this aggressive and challenging form of breast cancer.
Sep 18, 2024
Read moreResearchers found that breastfeeding was feasible for the majority of patients with hormone receptor-positive breast cancer who gave birth in the POSITIVE trial. Nearly two-thirds breastfed and more than 50 percent did so for more than 4 months, according to findings presented during ESMO 2024 Congress in Barcelona (Abstract 1814O).
September 16, 2024
Read moreThe NATALEE trial has revealed promising results for younger women with hormone receptor-positive (HR+), HER2-negative early breast cancer (EBC). Research shows that ribociclib (RIB), when paired with a nonsteroidal aromatase inhibitor (NSAI), significantly improves invasive disease-free survival (iDFS). This breakthrough is particularly notable for women under 40, a group historically associated with more aggressive disease and poorer outcomes.
September 16, 2024
Read moreOverall survival (OS) results from the Phase III, KEYNOTE-522 study showed a statistically significant and clinically meaningful improvement in OS among patients with high-risk, early-stage triple-negative breast cancer (TNBC) who were treated with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab versus those who received neoadjuvant chemotherapy alone (Abstract LBA4).
September 16, 2024
Read more